Pay in 4 interest-free payments of $5.99 Learn more
Ships within 48 hours · Estimated delivery Oct 25 - Oct 30
Harper's Bazaar (in Korean)
European Journal of Pharmacology 68(1-3):209-17
All treatments are administered by licensed clinicians in a professional setting focused on comfort and safety
547 The Phase III trial of olpasiran aims to compare its effects with the placebo on the risk of coronary heart disease death, myocardial infarction, and urgent coronary revascularization in ASCVD patients with elevated Lp(a), with results expected by 2026 (NCT05581303)
10.1038/s41591-019-0423-5 21
US$ 25.24
US$ 24.93
US$ 25.24
US$ 29.30
US$ 27.98
US$ 29.06
US$ 27.42
